Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of TS-142 (Vornorexant) in Healthy Subjects
NCT05707897Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vornorexant in Insomnia (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Plasma concentration of TS-142 and Pharmacokinetic parameters. Started Feb 2023; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05707897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707897.